Identification of pathogens for differential diagnosis of fever with jaundice in the Central African Republic: a retrospective assessment, 2008–2010

Christelle Luce Bobossi Gadia¹, Alexandre Manirakiza²*, Gaspard Tekpa³, Xavier Konamna¹, Ulrich Vickos¹ and Emmanuel Nakoune¹

Abstract

Background: Febrile jaundice results clinically in generalized yellow coloration of the teguments and mucous membranes due to excess plasma bilirubin, accompanied by fever. Two types are found: conjugated and unconjugated bilirubin jaundice. Jaundice is a sign in several diseases due to viruses (viral hepatitis and arbovirus), parasites (malaria) and bacteria (leptospirosis). In the Central African Republic (CAR), only yellow fever is included on the list of diseases for surveillance. The aim of this study was to identify the other pathogens that can cause febrile jaundice, for better management of patients.

Methods: Between 2008 and 2010, 198 sera negative for yellow fever IgM were randomly selected from 2177 samples collected during yellow fever surveillance. Laboratory analyses targeted four groups of pathogens: hepatitis B, C, delta and E viruses; dengue, chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley arboviruses; malaria parasites; and bacteria (leptospirosis).

Results: Overall, 30.9% sera were positive for hepatitis B, 20.2% for hepatitis E, 12.3% for hepatitis C and 8.2% for malaria. The majority of positive sera (40.4%) were from people aged 16–30 years. Co-infection with at least two of these pathogens was also found.

Conclusion: These findings suggest that a systematic investigation should be undertaken of infectious agents that cause febrile jaundice in the CAR.

Keywords: Febrile jaundice, Differential diagnosis, Central African Republic

Background

Febrile jaundice, a frequent symptom of certain infectious diseases, appears clinically as a generalized yellow coloration of the integuments and mucous membranes, due to excess plasma bilirubin, and is accompanied by fever >37.5 °C in the morning and 38 °C in the evening. It may be due secondarily to the release of a pyrogenic substance or of haemoglobin into the blood due to haemolysis or to cholestasis, with a decrease or halt in biliary secretion of intra- or extra-hepatic origin [1–4].

In low- and middle-income countries, predominantly in sub-Saharan Africa, febrile jaundice usually occurs in the presence of parasitic infections (malaria, toxoplasmosis, schistosomiasis), bacterial infections (typhoid, typhus, borreliosis, leptospirosis) or viral infections (hepatitis and Lassa, Marburg, Ebola, Crimean–Congo and Hantaa viral haemorrhagic fevers, cytomegalovirus, mumps, measles, rubella and Coxackievirus) and is sometimes present in sickle-cell disease [3–11]. These infections are major public health problems in the region, and understanding of their local epidemiology could indicate differential diagnoses [12].

For over a decade, the World Health Organization (WHO) has conducted epidemiological surveillance for
yellow fever in countries such as the Central African Republic (CAR). Operationally, any case of febrile jaundice is considered a suspected case of yellow fever and must be tested for yellow fever antigen (immunoglobulin M, IgM) in a qualified national laboratory. Samples that are negative for IgM suggest the involvement of other pathogens. In the CAR, 3220 suspected cases of yellow fever were reported to the reference laboratory for haemorrhagic fever at the Institut Pasteur of Bangui between 2007 and 2012; of these, 55 were positive [13]. We designed an exploratory study to identify the pathogens in the samples that were negative for yellow fever.

Methods

Database and target population

Data from nationwide serosurveillance for yellow fever between 1 January 2008 and 31 December 2010 were analysed retrospectively. The data are in the Epi Info database (Centers for Diseases Control and Prevention, Atlanta (GA), United States of America), which also contains information on the samples and sociodemographic data on the donors. The patients who gave samples met the WHO standard definition of suspected cases of yellow fever, i.e. any person with acute onset of fever and jaundice appearing within 14 days of onset of the first symptoms [14]. The samples consisted of 1–5 mL of venous blood drawn into dry tubes and transported in refrigerated sample carriers at 4–8 °C to the national reference laboratory at the Institut Pasteur of Bangui. The transport was ensured by trained focal points at CAR regional health facilities. The data obtained for each patient were: age, sex, location, symptoms (fever and jaundice or any sign of bleeding), history of vaccination against yellow fever, date of onset of symptoms and dates of blood sampling and transport to the laboratory. Serum was separated from each patient’s blood sample within 24 h and tested for yellow fever virus-specific fever IgM by enzyme-linked immunosorbent assay (ELISA). Positive results with ELISA were confirmed by quantitative polymerase chain reaction (qPCR). The remaining serum samples were stored at −20 °C at the Institut Pasteur of Bangui.

Selection of samples and identification of pathogens

As the purpose of this study was to differentiate yellow fever from other infections that present with similar features (acute fever and jaundice), only samples that were negative for yellow fever were selected. The codes of 2177 samples negative for yellow fever IgM were entered on an Excel spreadsheet from laboratory registers, and 198 samples were randomly selected for this study on the basis of the availability of testing reagents. The corresponding serum samples were identified in the storage freezer. Four groups of pathogens were targeted: hepatitis B, C, delta and E viruses; dengue, chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley arboviruses; malaria parasites; and bacteria (leptospirosis). The appropriate laboratory technique was used to identify each pathogen.

ELISA was used to screen for hepatitis, with a Murex™ Diasorin kit for hepatitis B virus (to detect hepatitis B surface antigen), antigen detection of hepatitis delta (HD) virus and a Monolisa™ HCV Ag-Ab ULTRA kit (Bio-Rad) for hepatitis C virus (HCV). Leptospirosis infection was diagnosed with the Panbio Leptospira IgM ELISA (Standard Diagnostics, Republic of Korea). The results were interpreted according to the manufacturers’ recommendations. Hepatitis E (HEV), dengue (DENV), chikungunya (CHIKV), Zika virus (ZIKV), Crimean–Congo haemorrhagic fever (CCHFV), West Nile virus (WNV) and Rift Valley (RVFV) infections were detected by qPCR [15–22]. The sequences of primers and probes used to identify these viruses are presented in Table 1.

Malaria was diagnosed with Standard Diagnostics Bio-line Ag-Pf and Ag-pan (Standard Diagnostics, Ref 05FK60, Republic of Korea), which contains antibodies targeting both PfHRP2 and lactate dehydrogenase specific to P. falciparum and other Plasmodium species (P. vivax, P. ovale and P. malariae).

Data analysis

Stata 11.0 software was used to calculate proportions of test results. The results were compared according to sociodemographic characteristics with the chi-2 test. Statistical significance was assessed at P < 0.05.

Results

Evidence of infection with at least one pathogen was found in 49.0% of samples (n = 97). Males under 35 years of age were the most commonly infected, but the difference was not statistically significant (P = 0.567 and 0.118, respectively). Of the 131 samples, 66.2% were from Bangui, the capital of the CAR, and its surrounding area, Ombella M’Poko (Table 2).

The predominant pathogens were hepatitis B (51.5%; 50/97), E (33.0%; 32/97) and C viruses (20.6%; 20/97). Co-infections were frequent, at a rate of 25.8% (25/97). Analyses for other pathogens (leptospirosis, DENV, CHIK and Zika, CCHV, WNV and RVFV) yielded negative results. The results for 16 patients showed co-infection with hepatitis B, E and C viruses (Table 3).

Discussion

Almost half the samples from patients presenting with fever and jaundice contained at least one infectious agent. Hepatitis B, C and E viruses were the most common pathogens identified in our samples; these infections are endemic in the CAR [23, 24]. The prevalence
of hepatitis B virus infection was higher than that found previously in the CAR by Komas et al., at 10.6% [25]; however, those authors collected samples from apparently healthy individuals, while we studied patients presenting with clinical symptoms.

HDV is a satellite of hepatitis B virus, and infection with this virus aggravates acute and chronic liver disease. A review of the literature shows strong variations in the prevalence of this virus among Africans seropositive for HBsAg, and the presence of this marker may constitute support for the argument that it plays a role in the development of HBsAg-associated liver diseases [26]. A study conducted in the CAR in 1989 showed that delta virus was the cause of fulminating hepatitis with severe jaundice in 124 cases [27]. In another study, however, it was much more common in patients with chronic liver disease [28].

Hepatitis E virus is endemic in central Africa, due mainly to poor environmental hygiene, a deteriorating health network and very poor epidemiological surveillance. Hepatitis E virus outbreaks were reported, for example, in 2002, 2004 and 2005 in Bangui [29, 30], and imported hepatitis E virus was documented in 2011, prompting implementation of the International Health Regulations (2005) in the CAR [31].

Severe malaria caused exclusively by P. falciparum in the CAR is also considered in people presenting with febrile jaundice, as this disease is endemic in the area.
In severe malaria, jaundice is related to severe haemolysis, hepatocellular damage, drug toxicity or a combination [32–34]. Co-infections with these pathogens are alarming because of their potential synergy in hepatitis dysfunction. The co-existence of malaria and viral hepatitis in developing countries like the CAR may thus present a diagnostic dilemma and severe complications and delay treatment [35].

We did not identify most of the less prevalent infections, such as leptospirosis, dengue, chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley viruses; and *P. falciparum*, sufficient quantities of serum remained for testing only a further 162 samples [36]. Co-infections with these pathogens might also yield positive results for other infectious pathogens [38] that have life-threatening synergistic effects.

### Conclusions

This study shows that acute hepatitis virus infections are still an important problem in the CAR. It is therefore essential to scale up hepatitis B vaccination and improve sanitation and environmental hygiene. Moreover, clinicians should be sensitized to the diagnostic dilemma of patients presenting with febrile jaundice. This study provides data on the prevalence of these diseases and the possibility of epidemics. Nationwide surveillance for yellow fever should be complemented by a survey of hepatitis viruses and other emerging haemorrhagic infections.

#### Acknowledgements

We thank the Ministry of Health, health professionals in the various health facilities, the WHO Representative and nongovernmental organizations in the CAR for transporting samples to the laboratory and for diagnostic reagents. We also thank all the patients who participated in this study. We are also grateful to Professeur Elisabeth Heseltine for her support in editing this manuscript.

#### Funding

The Institut Pasteur de Bangui and the Ministry of Health in the CAR supported the study financially. National surveillance of yellow fever and the pathogens targeted in this analysis was funded by WHO.

#### Availability of data and materials

The datasets generated and analysed during the current study is not publicly available because it contains potentially identifiable information but is available from the corresponding author on reasonable request.

#### Authors’ contributions

CLBG supervised the field activities, participated in collecting data, analysed and interpreted the data and wrote the manuscript. AM prepared the questionnaire and analysed and interpreted the data. GT contributed to writing the manuscript. XK performed the ELISA tests. UV contributed to the analysis and interpretation of the data. EN designed the study and directed it, supervised all the field activities and contributed to the analysis and interpretation of the data. All the authors participated in writing this draft and approved the final version of the manuscript for publication.

#### Ethics approval and consent to participate

This surveillance programme was approved by the expert committee for the yellow fever control programme of the Ministry of Health in CAR. As rational surveillance is performed for transmissible diseases subject to mandatory declaration in the country (yellow fever and other haemorrhagic fevers), patient consent was not necessary.

#### Consent for publication

Not applicable.

### Table 3 Pathogens identified in samples negative for yellow fever IgM, CAR, 2008–2010

| Infectious agent | No. of samples tested | No. positive (%) |
|------------------|-----------------------|------------------|
| HBsAg            | 162                   | 32 (19.8)        |
| HEV              | 198                   | 27 (13.6)        |
| HCVag            | 198                   | 9 (5.6)          |
| *P. falciparum*   | 198                   | 4 (2.0)          |
| Anti-HD           | 50                    | 17 (34.0)        |
| HEV + HBsAg      | 162                   | 6 (3.7)          |
| HBsAg + HCVag    | 162                   | 4 (2.5)          |
| HBsAg + *P. falciparum* | 162 | 4 (2.5)          |
| HCVag + HEV      | 162                   | 2 (1.2)          |
| HEV + *P. falciparum* | 198 | 2 (1.0)          |
| HBsAg + HEV + *P. falciparum* | 162 | 2 (1.2)          |
| HBsAg + HEV + HCVag | 162 | 1 (0.6)          |
| HBsAg + HCVag + *P. falciparum* | 162 | 1 (0.6)          |
| Other pathogens  | 198                   | 0 (0.0)          |

*After testing sera for leptospirosis; dengue arbovirus; chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley viruses; and *P. falciparum*, sufficient quantities of serum remained for testing only a further 162 samples*

*Hepatitis E virus, tested with qPCR*

*Hepatitis delta virus*

*Leptospirosis; DENV; CHIK, ZIKV, CCHFV, WNV and RVFV*
References
1. Chung JP, Kim KW, Chi HS, Lee SI, Shin ET, Cho JH, et al. Obstructive jaundice due to compression of the common hepatic duct by right hepatic artery—a case associated with the absence of the lateral segment of the left hepatic lobe. Yonsei Med J. 1994;35(2):231–8.
2. Chang K, Yen JJ, Lee HC, Liu KH, Lee NY, Ko WC, et al. Acute h. With or without jaundice: a predominant presentation of acute Q fever in southern Taiwan. J Microbiol Immunol Infect. 2004;37(2):103–8.
3. Shah S, Ali L, Sattar RA, Aiz T, Ansari T, Ara J. Malarial hepatopathy in falciarpin malaria. J Coll Physicians Surg Pak. 2009;19(6):367–70.
4. L’Azou M, Succo T, Kamagate M, Ouattara A, Gilbernair E, Adjogoua E, et al. Evaluation of chikungunya diagnostic assays: differences in sensitivity of serology assays in two independent outbreaks. PLoS Negl Trop Dis. 2010;4(7):e753.
5. Lanciotti RS, Kerst AJ, Nasri RS, Godsey MS, Mitchell CJ, Savage HM, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-polymerase chain reaction assay for diagnosis of dengue infections. Am J Trop Med Hyg. 2008;79(4):505–10.
6. Vasilouka P, Kralik P, Slana I, Pavlik I. Optimisation of a triplex real time RT-PCR for detection of hepatitis E virus RNA and validation on biological samples. J Virol Meth. 2012;180(1):239–42.
7. Accame J, Leins LM, Masure AH, Diallo M, Diallo M, Weidmann M, et al. Quantitative real-time PCR detection of Zika virus and evaluation with field-caught mosquitoes. Virol J. 2013;10:311.
8. Yap G, Pok KY, Lai YL, Hapuarachchi H, Chow A, Leo YS, et al. Evaluation of high prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. J Med Virol. 1995;46(3):269–72.
9. Andernach C, Olinger CM, Boua N, Talarmin A, Venard Y, Muller CP, et al. Characterization of hepatitis B virus strains from the Central African Republic: preliminary results. Pathol Biol (Paris). 2008;56(5):310–3.
10. Rose HD, Lentino JR, Mavrelis PG, Rytel MW. Jaundice associated with nonhepatic sepsis in the child: a reevaluation of case definitions, October 2010. Wkly Epidemiol Rec. 2010;85:461–6.
11. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR assay. J Clin Microbiol. 2000;38(11):4066–71.
12. Djomani S, Médard M, Gueye M, Doumbia A, Malouf S, et al. Infection due to hepatitis delta virus in Africa: report from Senegal and review. Clin Infect Dis. 1992;14(2):510–4.
13. Lehmann T, Kretzschmar A, Schilling S, Schilling S, Asper M, Panning M, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-polymerase chain reaction assay for diagnosis of dengue infections. Am J Trop Med Hyg. 2008;79(4):505–10.
14. Vasilouka P, Kralik P, Slana I, Pavlik I. Optimisation of a triplex real time RT-PCR for detection of hepatitis E virus RNA and validation on biological samples. J Virol Meth. 2012;180(1):239–42.